Botanix Opens Investor Webinar Registration as Sofdra Launch Advances

An announcement from Botanix Pharmaceuticals Limited ( (AU:BOT) ) is now available.

Botanix Pharmaceuticals, a commercial dermatology company based in Philadelphia and Phoenix, develops and markets innovative skin treatments, led by Sofdra, the first FDA‑approved new chemical entity for primary axillary hyperhidrosis. The drug addresses a major unmet need for patients who have had limited effective options for this socially burdensome condition.

The company has opened registration for an investor webinar on 3 March 2026, where senior executives will present and discuss its Half Year Financial Report. The event signals an effort to enhance transparency and engagement with investors, potentially offering fresh insight into the early commercial performance of Sofdra and Botanix’s broader financial and strategic outlook.

The most recent analyst rating on (AU:BOT) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

More about Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited is a commercial dermatology company based in Philadelphia and Phoenix that focuses on treatments for skin conditions. Its lead product, Sofdra, is the first and only new chemical entity approved by the U.S. FDA to treat primary axillary hyperhidrosis, offering a novel, safe and effective option for patients with this socially challenging disorder.

The company targets the dermatology market with a focus on innovative therapies that address significant unmet medical needs. By commercialising Sofdra for excessive underarm sweating, Botanix is positioning itself as a specialist player in a niche yet impactful segment of the global dermatology and hyperhidrosis treatment landscape.

Average Trading Volume: 7,888,809

Technical Sentiment Signal: Sell

Current Market Cap: A$124.2M

See more data about BOT stock on TipRanks’ Stock Analysis page.